Steady-state kinetics of valproic acid in epileptic patients. 1978

J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal

Pharmacokinetic evaluation and prediction were carried out in 20 epileptic patients. Using conventional pharmacokinetic techniques and a one-compartment model, predicted and observed valproic acid plasma concentrations were compared. Valproic acid assay was performed by gas-liquid chromatography. There was good agreement between predicted and observed plasma concentrations. Most patients had predicted half-lives (t1/2s) of 6 to 8 hr, independent of the plasma concentration of valproic acid. Five patients had predicted t1/2s of 12 hr. The correlation between dose and plasma level was poor. Most patients had valproic acid plasma levels between 55 and 100 microgram/ml. Administration of valproic acid three times a day with determination of individual plasma concentrations offers a reliable method of monitoring. Constant levels are maintained in individual patients, but there is substantial intersubject variation.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid

Related Publications

J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
January 1982, Clinical pharmacokinetics,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
January 1991, International journal of clinical pharmacology research,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
June 1983, Therapeutic drug monitoring,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
November 1984, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
August 1977, Journal of pharmaceutical sciences,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
March 1998, Biological & pharmaceutical bulletin,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
January 1984, World review of nutrition and dietetics,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
November 1977, Psychopharmacology,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
October 1996, East African medical journal,
J Bruni, and B J Wilder, and L J Willmore, and R J Perchalski, and H J Villarreal
October 1975, British journal of clinical pharmacology,
Copied contents to your clipboard!